Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits

Neurobiology of Disease

Volumn 47, Issue 2, 2012, Pages 258-267

  Hallett, Penelope J ^a   McLean, Jesse R ^a   Kartunen, Andrew ^a   Langston, J William ^b   Isacson, Ole ^a  

^a MCLEAN HOSPITAL   (United States)

^b PARKINSON S INSTITUTE   (United States)

Author keywords

Alpha synuclein; Autonomic; Axonopathy; Constipation; Gastrointestinal; Parkinson's disease; Synucleinopathy

Indexed keywords

ALPHA SYNUCLEIN; PROTEINASE K;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CADAVER; CENTRAL NERVOUS SYSTEM; CONSTIPATION; CONTROLLED STUDY; FOOD INTAKE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL TRACT; INTESTINE INNERVATION; INTESTINE TRANSIT TIME; LARGE INTESTINE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYMPTOMATOLOGY; TRANSGENIC MOUSE; WATER CONTENT; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; AUTONOMIC NERVOUS SYSTEM DISEASES; GASTROINTESTINAL TRACT; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; URINARY BLADDER;

EID: 84861706581     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.04.009     Document Type: Article

References (61)

1. Abbott R.D., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001, 57:456-462.
2. Abbott R.D., et al. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J. Neurol. 2003, 250(Suppl. 3):III30-III39.
3. Anderson G., et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp. Neurol. 2007, 207:4-12.
4. Beach T.G., et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119:689-702.
5. Braak E., et al. Alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol. 2001, 101:195-201.
6. Braak H., et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 2006, 396:67-72.
7. 123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol. Scand. 1998, 97:307-314.
8. Burre J., et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329:1663-1667.
9. Cannon J.R., Greenamyre J.T. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog. Brain Res. 2010, 184:17-33.
10. Chaudhuri K.R., et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
11. Chaumette T., et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol. Motil. 2009, 21:215-222.
12. Chesselet M.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?. Exp. Neurol. 2008, 209:22-27.
13. Chesselet M.F., et al. Strengths and limitations of genetic mouse models of Parkinson's disease. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S84-S87.
14. Chung C.Y., et al. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci. 2009, 29:3365-3373.
15. Cookson M.R., Bandmann O. Parkinson's disease: insights from pathways. Hum. Mol. Genet. 2010, 19:R21-R27.
16. Dabby R., et al. Skin biopsy for assessment of autonomic denervation in Parkinson's disease. J. Neural Transm. 2006, 113:1169-1176.
17. Dawson T.M., et al. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
18. Drolet R.E., et al. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol. Dis. 2009, 36:96-102.
19. Fernagut P.O., et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 2007, 61:991-1001.
20. Fleming S.M., et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci. 2004, 24:9434-9440.
21. Fleming S.M., et al. Alterations in baroreceptor function in transgenic mice overexpressing human alpha-synuclein. Program No. 50.9. 2007 Neuroscience Meeting Planner 2007, Society for Neuroscience, San Diego, CA, Online.
22. Fleming S.M., et al. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur. J. Neurosci. 2008, 28:247-256.
23. Fleming S.M., et al. Alterations in heart rate variability in transgenic mice overexpressing human wildtype alpha synuclein Program No. 531.9. 2009 Neuroscience Meeting Planner 2009, Society for Neuroscience, Chicago, IL, Online.
24. Fujishiro H., et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov. Disord. 2008, 23:1085-1092.
25. Gai W.P., et al. Age-related loss of dorsal vagal neurons in Parkinson's disease. Neurology 1992, 42:2106-2111.
26. Gallagher D.A., et al. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. Mov. Disord. 2010, 25:2493-2500.
27. Ghebremedhin E., et al. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol. 2009, 118:777-784.
28. Goldstein D.S. Neuroscience and heart-brain medicine: the year in review. Cleve. Clin. J. Med. 2010, 77(Suppl. 3):S34-S39.
29. Goldstein D.S., et al. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 2000, 133:338-347.
30. Goldstein D.S., et al. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Cleve. Clin. J. Med. 2009, 76(Suppl. 2):S47-S50.
31. Greene J.G., et al. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp. Neurol. 2009, 218:154-161.
32. Greten-Harrison B., et al. Alphabetagamma-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19573-19578.
33. Jellinger K.A. Synuclein deposition and non-motor symptoms in Parkinson disease. J. Neurol. Sci. 2011, 310:107-111.
34. Kuo Y.M., et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum. Mol. Genet. 2010, 19:1633-1650.
35. Lams B.E., et al. Loss of transmitter-associated enzyme staining following axotomy does not indicate death of brainstem cholinergic neurons. Brain Res. 1988, 475:401-406.
36. Lebouvier T., et al. The second brain and Parkinson's disease. Eur. J. Neurosci. 2009, 30:735-741.
37. Lebouvier T., et al. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 2010, 5:e12728.
38. Magen I., Chesselet M.F. Genetic mouse models of Parkinson's disease The state of the art. Prog. Brain Res. 2010, 184:53-87.
39. McLean J.R., et al. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell. Neurosci. 2012, 49:230-239.
40. 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J. Neurol. Sci. 2006, 243:101-104.
41. Natale G., et al. MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut. Brain Res. 2010, 1355:195-206.
42. Nemani V.M., et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66-79.
43. Neumann M., et al. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol. 2000, 100:568-574.
44. Orimo S., et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol. 2007, 17:24-30.
45. Orimo S., et al. Cardiac sympathetic denervation in Parkinson's disease linked to SNCA duplication. Acta Neuropathol. 2008, 116:575-577.
46. Orimo S., et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008, 131:642-650.
47. Pfeiffer R.F. Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S94-S97.
48. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 2011, 17:10-15.
49. Phillips R.J., et al. Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat. Exp. Neurol. 2009, 220:109-119.
50. Rockenstein E., et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 2002, 68:568-578.
51. Savica R., et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009, 73:1752-1758.
52. Savica R., et al. When does Parkinson disease start?. Arch. Neurol. 2010, 67:798-801.
53. Song D.D., et al. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 2004, 186:158-172.
54. Taylor T.N., et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 2009, 29:8103-8113.
55. Tian Y.M., et al. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease. Neuroscience 2008, 153:634-644.
56. Ulusoy A., et al. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog. Brain Res. 2010, 184:89-111.
57. Wakabayashi K., et al. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol. 1988, 76:217-221.
58. Wang L., et al. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 2008, 19:873-876.
59. Watson J.B., et al. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 2009, 159:501-513.
60. Zesiewicz T.A., et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010, 74:924-931.
61. Ziemssen T., Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J. Neurol. Sci. 2010, 289:74-80.